This company has been marked as potentially delisted and may not be actively trading. NASDAQ:JNP Juniper Pharmaceuticals (JNP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Juniper Pharmaceuticals Stock (NASDAQ:JNP) 30 days 90 days 365 days Advanced Chart Get JNP alerts:Sign Up Key Stats Today's Range$11.45▼$11.5050-Day Range N/A52-Week Range$4.30▼$13.25Volume28,513 shsAverage Volume155,873 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewJuniper Pharmaceuticals, Inc., a diversified healthcare company, focuses on developing novel intra-vaginal therapeutics that address unmet medical needs in women's health. It operates in two segments, Product and Service. The company develops its products utilizing its proprietary drug delivery technologies, which include bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa to achieve sustained and controlled delivery of active drug product; and a novel intravaginal ring technology. Juniper Pharmaceuticals, Inc. markets Crinone, a progesterone bioadhesive vaginal gel for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency. Its product candidates include JNP-0101, which is designed to deliver oxybutynin for the treatment of overactive bladder in women; JNP-0201, which contains natural progesterone and estradiol to be used for hormone replacement therapy in menopausal women; and JNP-0301, a natural progesterone for the prevention of preterm birth in women with a short cervical length. The company offers pharmaceutical product development; clinical trial manufacturing; and analytical and consulting services. Juniper Pharmaceuticals, Inc. has collaboration agreements with Merck KGaA and Allergan, as well as patent license agreement with Massachusetts General Hospital. The company was formerly known as Columbia Laboratories, Inc. and changed its name to Juniper Pharmaceuticals, Inc. in April 2015. Juniper Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Boston, Massachusetts.Read More… Receive JNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Juniper Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address JNP Stock News HeadlinesJuniper Networks invests in AI startup Recogni in $102 million funding roundNovember 13, 2024 | reuters.comAnalysts’ Opinions Are Mixed on These Technology Stocks: Viavi Solutions (VIAV), Silicon Laboratories (SLAB) and Juniper Networks (JNPR)November 1, 2024 | markets.businessinsider.comTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new blockchain development…May 3, 2025 | Crypto 101 Media (Ad)Juniper beats quarterly estimates on networking gear demandOctober 31, 2024 | reuters.comJuniper Networks revenue misses estimates on weak client spendingJanuary 30, 2024 | msn.comWhy Juniper Networks Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving PremarketJanuary 9, 2024 | msn.comJuniper Networks Stock (NYSE:JNPR), Analyst Ratings, Price Targets, PredictionsNovember 24, 2023 | benzinga.comJuniper Essential Oil Market : Reliable Business Data Analysis and Forecast by 2028 with Top Countries DataOctober 20, 2022 | marketwatch.comSee More Headlines JNP Stock Analysis - Frequently Asked Questions How were Juniper Pharmaceuticals' earnings last quarter? Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) announced its earnings results on Thursday, August, 9th. The specialty pharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by $0.18. The specialty pharmaceutical company earned $15.31 million during the quarter, compared to analyst estimates of $16.30 million. What other stocks do shareholders of Juniper Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Juniper Pharmaceuticals investors own include Novavax (NVAX), Bristol-Myers Squibb (BMY), Verastem (VSTM), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Rigel Pharmaceuticals (RIGL) and Synergy Pharmaceuticals (SGYP). Company Calendar Last Earnings8/09/2018Today5/03/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:JNP CIK821995 Webwww.juniperpharma.com Phone617-639-1500FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:JNP) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Juniper Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Juniper Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.